CTIS2024-512138-13-00招募中1 期
A PHASE 2, OPEN-LABEL, RANDOMIZED, NON-COMPARATIVE CLINICAL TRIAL OF ADP-A2M4CD8 MONOTHERAPY AND IN COMBINATION WITH NIVOLUMAB IN SUBJECTS WITH RECURRENT OVARIAN CANCERS(SURPASS-3 STUDY/ GOG-3084) - ADP-0055-003
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 66
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
入选标准
- •Subject (or legally authorized representative) has voluntarily agreed to participate by giving written informed consent in accordance with International Council for Harmonisation (ICH) Good Clinical Practice (GCP) guidelines and applicable local regulations., Subject has left ventricular ejection fraction (LVEF) of = 50% or the institutional lower limit of normal range, whichever is lower., Subject is fit for leukapheresis, and adequate venous access can be established for the cell collection., Subjects of childbearing potential must have a negative urine or serum pregnancy test AND must agree to use a highly effective method of contraception starting at the firstdose of chemotherapy and continue for at least 12 months or for 4 months after the gene-modified cells are no longer detected in the blood, or 6 months after the last dose of nivolumab, whichever is longer. Subjects of childbearing potential must also agree to refrain from egg donation, storage, or banking during these same time periods., Subject (or legally authorized representative) has agreed to abide by all protocol-required procedures including study-related assessments and management by the treating institution for the duration of the study, including LTFU., Subject is = 18 and = 75 years of age at the time the Pre-Screening informed consent form (ICF) is signed., Subject has histologically confirmed diagnosis of high-grade serous or high-grade endometrioid recurrent ovarian carcinoma, including primary peritoneal and fallopian tube carcinoma., Subject has measurable disease according to RECIST v1.1 prior to lymphodepletion. Measurable disease is not required prior to leukapheresis., Subject has the following disease-specific prior therapy requirements: a. The initial therapy must have included at least 3 cycles of a prior platinum and taxane based chemotherapy regimen for primary disease, possibly including intraperitoneal therapy, consolidation, or extended therapy (maintenance/consolidation). b. Subjects may receive up to 4 prior regimens of combination or single agent systemic treatment for their disease, which may include investigational therapies unless discussed and agreed upon with the Sponsor or designee. Note: Neo-adjuvant/adjuvant treatment is considered as one line of treatment. Bridging therapy is permitted and is not considered as a line of treatment. c. Subjects who have received only 1 line of platinum based therapy must have progressed between 93 and 183 days of completing platinum based therapy as a part of front line treatment of ovarian cancer. Subjects who have progressed within 92 days of completing platinum based therapy in front line treatment are excluded. d. Subjects who have received 2 or more lines of platinum based therapy must have progressed during or within 183 days of completing the latest platinum based therapy for treatment of recurrent ovarian cancer. The number of days (platinum free interval) should be calculated from the date of the last administered dose of platinum therapy to the date of documentation of progression. e. Subjects with a known BRCA mutation (germ line or somatic) must have received a poly adenosine diphosphate-ribose polymerase inhibitor (PARPi). f. Subjects must have received bevacizumab., Positive for HLA-A*02:01, HLA-A*02:02, HLA-A*02:03, or HLA- A*02:06 allele as determined by Adaptimmune-designated central laboratory testing. HLA-A*02 alleles having the same protein sequence in the peptide binding domains (P
排除标准
- •Positive for HLA-A*02:05 in either allele as determined by Adaptimmune-designated central laboratory. HLA-A*02 alleles having the same protein sequence as HLA-A*02:05 in the peptide binding domains (P groups) will also be excluded. Other alleles may be exclusionary after adjudication with the Sponsor., Subject has received or plans to receive the following therapy/treatment prior to leukapheresis or lymphodepleting chemotherapy, unless stopped according to the washout requirements: Note: The washout periods are provided as a guideline in the table below. For Spain only, minor modifications to washout periods, if assessed as not clinically significant by the site study Investigator or designee, may be acceptable after discussing with the Sponsor Study Physician. (for full details please refer to section 5.3 of the study protocol (Exclusion Criteria 2. ), Toxicity from previous anti-cancer therapy that has not recovered to Grade = 1 or baseline prior to enrollment (except for nonclinically significant toxicities, e.g., alopecia and vitiligo). Subjects with Grade 2 toxicities that are deemed stable or irreversible (e.g., peripheral neuropathy) can be enrolled., Subject has a history of allergic reactions attributed to compounds of similar chemical or biologic composition to fludarabine, cyclophosphamide, or other agents used in the study., Subject has an active autoimmune or immune-mediated disease that has not yet resolved. Subjects with immune-mediated AEs secondary to treatment with immunotherapy that resolve to Grade = 1 off steroids are permitted. Subjects with hypothyroidism, type I diabetes, adrenal insufficiency, or pituitary insufficiency that are stable on replacement therapy are eligible. Subjects with disorders such as asthma, vitiligo, psoriasis, or atopic dermatitis that are well controlled without requiring systemic immunosuppression are also eligible. Other stable immune conditions that do not require prednisone > 20 mg/day (or its equivalent for other corticosteroid agents) may be acceptable with the agreement of the Sponsor., Subject had major surgery within 4 weeks prior to lymphodepletion; subjects should have been fully recovere from any surgical-related toxicities. Surgical-related toxicities which are not clinically significant per Investigator assessment may be acceptable after discussion and agreement with Study Physician., Leptomeningeal disease, carcinomatous meningitis, or symptomatic central nervous system (CNS) metastases. Subjects with prior history of symptomatic CNS metastases must have received treatment (i.e., SRS, WBRT, or surgery) and be neurologically stable for at least 1 month, not requiring anti-seizure medications, and off of steroids for at least 14 days prior to leukapheresis and lymphodepletion. Subjects who have asymptomatic CNS metastases without associated edema, shift, or requirement for steroids or antiseizure medications are eligible. If such a subject receives SRS or WBRT, a minimum period of 2 weeks needs to lapse between the therapy and lymphodepletion. Prophylactic anti- seizure medication is allowed., Subject has any other prior malignancy that is not considered by the Investigator to be in complete remission. Resectable squamous or basal cell carcinoma of the skin is acceptable. Prior malignancies that have been surgically resected and show no evidence of disease are acceptable., Clinically significant cardiovascular disease including, but not limited to, any of the following: a.
研究者
相似试验
招募中
1 期
A PHASE II STUDY OF ADJUVANT ATEZOLIZUMAB OR ATEZOLIZUMAB PLUS TIRAGOLUMAB IN SOLID TUMORS WITH RESECTABLE DISEASE WITH INTERMEDIATE-HIGH RISK OF RECURRENCE AND HIGH TUMOR MUTATIONAL BURDEN OR MICROSATELLITE INSTABILITY (IMperator)CTIS2024-512635-71-00Roche Farma S.A.40
进行中（未招募）
1 期
A Phase 2 trial using ARV-471 or Anastrozole in Post-Menopausal Women with Breast Cancer Prior to Surgery.Post-menopausal women with ER+ HER2– breast cancerMedDRA version: 23.0Level: LLTClassification code 10070575Term: Estrogen receptor positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 23.0Level: PTClassification code 10083232Term: HER2 negative breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-005081-17-DEArvinas Estrogen Receptor, Inc. (Arvinas)150
进行中（未招募）
1 期
This study is to assess the efficacy and safety of lenalidomide in combination with adriamycine and low dose dexamethasone in newly diagnosed patients with symptomatic multiple myeloma as well as to collect information regarding the effect of this regimen on angiogenesis and bone remodeling of the study population.ewly Diagnosed multiple myelomaMedDRA version: 17.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2011-001499-20-GRMeletios-Athanasios Dimopoulos
进行中（未招募）
1 期
A phase 2 study evaluating S 95005 plus bevacizumab and capecitabine plus bevacizumab in patients with previously untreated colorectal cancer who are non-eligible for intensive therapyMetastatic colorectal cancerMedDRA version: 21.0Level: PTClassification code 10052358Term: Colorectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-004544-18-GBInstitut de Recherches Internationales Servier153
进行中（未招募）
1 期
A phase 2 study evaluating S 95005 plus bevacizumab and capecitabine plus bevacizumab in patients with previously untreated colorectal cancer who are non-eligible for intensive therapyMetastatic colorectal cancerMedDRA version: 19.1Level: PTClassification code 10052358Term: Colorectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-004544-18-NLInstitut de Recherches Internationales Servier150